Trial
NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Intervention
Part 1 (Dose Escalation): Duvortuxizumab
Why stopped
Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-20